# OnCo record b-subclone-attribution-residual-disease (bottleneck). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/bottlenecks/b-subclone-attribution-residual-disease/>
  a schema:Thing ;
  onco:kind "bottleneck" ;
  schema:identifier "b-subclone-attribution-residual-disease" ;
  schema:name "Naming which clone or phenotype is left after treatment"@en ;
  schema:alternateName "Subclone attribution of residual disease"@en, "Which clone remains"@en ;
  schema:description "Blood tests can now find a few parts per million of tumour DNA after treatment, but at those levels there are too few molecules to say which branch of the tumour is left, or whether it still carries the oestrogen receptor or TROP2."@en ;
  schema:url <https://onco.cc/bottlenecks/b-subclone-attribution-residual-disease/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/s41586-023-05776-4>, <https://doi.org/10.18632/oncotarget.28565>, <https://doi.org/10.1158/1078-0432.CCR-19-3005> ;
  onco:related <https://onco.cc/bottlenecks/b-dormancy-mrd/>, <https://onco.cc/bottlenecks/b-tumor-heterogeneity/>, <https://onco.cc/biomarkers/ctdna-mrd-positive/> ;
  onco:cancers <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/eclipse-subclone-ctdna/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/trop2/>, <https://onco.cc/targets/estrogen-receptor/> ;
  onco:trials <https://onco.cc/trials/trak-er/>, <https://onco.cc/trials/c-trak-tn/>, <https://onco.cc/trials/serena-6/>, <https://onco.cc/trials/pada-1/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-abbosh-tracerx-ctdna-relapse-nature-2023/>, <https://onco.cc/key-papers/paper-northcott-next-personal-validation-oncotarget-2024/>, <https://onco.cc/key-papers/paper-parsons-mrd-early-breast-cancer-clin-cancer-res-2020/>, <https://onco.cc/key-papers/paper-notini-trop2-pan-cancer-multiomic-npj-precis-oncol-2026/>, <https://onco.cc/key-papers/paper-coates-sacituzumab-resistance-tacstd2-cancer-discov-2021/>, <https://onco.cc/key-papers/paper-abbosh-phylogenetic-ctdna-lung-cancer-nature-2017/>, <https://onco.cc/key-papers/paper-fiala-ctdna-early-detection-bmc-med-2018/> .